CTAS vs TRAW · P/E 51, rev $11.26B vs rev $2.8M
Cintas Corporation (CTAS) versus Traws Pharma Inc (TRAW) — a side-by-side from cached financials, not a winner call.
Cintas Corporation (CTAS) is a specialty business services company listed on US.
Traws Pharma Inc (TRAW) is a biotechnology company listed on NASDAQ.
Latest reported CTAS revenue for 2026-05-31 was $11.26B. Net income was $2.00B. Revenue was up 8.9% from 2025-05-31 to 2026-05-31. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
Latest reported TRAW revenue for 2025-09-30 was $2.8M. Net income was $16.6M. Revenue was up 2.1% from 2025-06-30 to 2025-09-30. TRAW currently screens at market cap $12.1M.
CTAS currently screens at market cap $89.01B and trailing P/E 51.3. TRAW currently screens at market cap $12.1M.
Not investment advice. Open the CTAS and TRAW stock pages for the full models.
Not investment advice.